中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(4): 818-825

Value of different Baveno Ⅶ-based criteria in screening for high-risk esophageal and gastric varices in advanced chronic liver disease

DOI: 10.3969/j.issn.1001-5256.2023.04.012
  • 1.

    Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

  • 2.

    Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research funding:

National Natural Science Foundation of China Youth Fund (81900505);

The Science and Technology Development Project of China State Railway Group (J2021Z609)

More Information
  • Corresponding author: WU Jing, wujing36youyi@ccmu.edu.cn (ORCID: 0000-0002-8255-1953)
  • Received Date: 2022-09-13
  • Accepted Date: 2022-11-09
  • Published Date: 2023-04-20
    Abstract
  •   Objective  To investigate the value of Baveno Ⅶ criteria versus Expanded Baveno Ⅶ criteria in screening for high-risk varices (HRV) in patients with compensated advanced chronic liver disease (cACLD).  Methods  A total of 146 patients with cACLD who were admitted to Beijing Shijitan Hospital, Capital Medical University, from January 2016 to December 2018 were enrolled, and according to the absence or presence of HRV based on gastroscopy, they were divided into HRV group with 68 patients and control group with 78 patients. Clinical data, liver stiffness measurement (LSM), and gastroscopy findings were analyzed, and different Baveno Ⅶ criteria were analyzed in terms of their sensitivity and specificity in the diagnosis of HRV. The Mann-Whitney U test and the McNemar test were used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. A univariate logistic regression analysis was performed for the variables used to predict HRV, and a multivariate analysis was performed for the variables with P < 0.1. The two sets of Baveno Ⅶ criteria were compared in terms of their sensitivity and specificity in the diagnosis of HRV.  Results  A total of 146 patients were enrolled in the study, among whom 68 (46.6%) were found to have HRV. The median age was 54 years (range 29-84 years), male patients accounted for 65.8%, and hepatitis B virus was the main etiology observed in 115 patients (78.8%). The univariate logistic regression analysis showed that LSM and platelet count (PLT) were associated with HRV (both P < 0.05). The multivariate analysis showed that based on Baveno Ⅶ criteria, LSM > 20 kPa or PLT < 150×109/L was associated with HRV (both P < 0.05), and based on Expanded Baveno Ⅶ criteria, LSM > 25 kPa or PLT < 110×109/L was associated with HRV (both P < 0.05). LSM and PLT had an area under the ROC curve of 0.797 (95% confidence interval [CI]: 0.723-0.859) and 0.789 (95% CI: 0.714-0.852), respectively, in the diagnosis of HRV. There were significant differences in the prevalence rates of esophageal and gastric varices and HRV between the patients who met Baveno Ⅶ criteria and those who did not meet such criteria (χ2=23.14 and 23.14, both P < 0.001), as well as between the patients who met Expanded Baveno Ⅶ criteria and those who did not meet such criteria (χ2=43.51 and 25.71, both P < 0.001). Although a higher proportion of patients were exempted from gastroscopy based on Expanded Baveno Ⅶ criteria (32.9% vs 13.7%), Baveno Ⅶ criteria had higher sensitivity (0.98 vs 0.88) and negative predictive value (0.95 vs 0.83) and could better avoid the missed diagnosis of HRV (1.0% vs 9.3%).  Conclusion  Baveno Ⅶ criteria are more suitable for the screening for HRV in cACLD patients in China.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013.
    [2]
    FORTUNE BE, GARCIA-TSAO G, CIARLEGLIO M, et al. Child-turcotte-pugh class is best at stratifying risk in variceal hemorrhage: analysis of a us multicenter prospective study[J]. J Clin Gastroenterol, 2017, 51(5): 446-453. DOI: 10.1097/MCG.0000000000000733.
    [3]
    SUN X, ZHANG A, ZHOU T, et al. Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial[J]. Hepatol Int, 2021, 15(3): 741-752. DOI: 10.1007/s12072-021-10155-0.
    [4]
    KIM DJ, CHOI MS. Life-sustaining treatment and palliative care in patients with liver cirrhosis-legal, ethical, and practical issues[J]. Clin Mol Hepatol, 2017, 23(2): 115-122. DOI: 10.3350/cmh.2017.0018.
    [5]
    LAU J, YU Y, TANG R, et al. Timing of endoscopy for acute upper gastrointestinal bleeding[J]. N Engl J Med, 2020, 382(14): 1299-1308. DOI: 10.1056/NEJMoa1912484.
    [6]
    GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [7]
    SUK KT. Hepatic venous pressure gradient: clinical use in chronic liver disease[J]. Clin Mol Hepatol, 2014, 20(1): 6-14. DOI: 10.3350/cmh.2014.20.1.6.
    [8]
    STAFYLIDOU M, PASCHOS P, KATSOULA A, et al. Performance of Baveno Ⅵ and Expanded Baveno Ⅵ criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(9): 1744-1755. e11. DOI: 10.1016/j.cgh.2019.04.062.
    [9]
    AUGUSTIN S, PONS M, MAURICE JB, et al. Expanding the Baveno Ⅵ criteria for the screening of varices in patients with compensated advanced chronic liver disease[J]. Hepatology, 2017, 66(6): 1980-1988. DOI: 10.1002/hep.29363.
    [10]
    IRANMANESH P, VAZQUEZ O, TERRAZ S, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma[J]. J Hepatol, 2014, 60(5): 969-974. DOI: 10.1016/j.jhep.2013.12.015.
    [11]
    PONS M, AUGUSTIN S, SCHEINER B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease[J]. Am J Gastroenterol, 2021, 116(4): 723-732. DOI: 10.14309/ajg.0000000000000994.
    [12]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
    [13]
    ABRALDES JG, BUREAU C, STEFANESCU H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The"Anticipate"study[J]. Hepatology, 2016, 64(6): 2173-2184. DOI: 10.1002/hep.28824.
    [14]
    QI XL. New techniques for diagnosis and monitoring of portal hypertension in liver cancer (Part)[J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2021, 15(1): 72. DOI: 10.3877/cma.j.issn.1674-1358.2021.01.101.

    祁小龙. 肝癌门静脉高压症诊断与监测新技术(上)[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15(1): 72. DOI: 10.3877/cma.j.issn.1674-1358.2021.01.101.
    [15]
    QI XL. New techniques for diagnosis and monitoring of portal hypertension in liver cancer (Part Ⅱ)[J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2021, 15(2): 144. DOI: 10.3877/cma.j.issn.1674-1358.2021.02.101

    祁小龙. 肝癌门静脉高压症诊断与监测的新技术(下)[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15(2): 144. DOI: 10.3877/cma.j.issn.1674-1358.2021.02.101
    [16]
    REVERTER E, TANDON P, AUGUSTIN S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding[J]. Gastroenterology, 2014, 146(2): 412-419. e3. DOI: 10.1053/j.gastro.2013.10.018.
    [17]
    European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
    [18]
    PALANIYAPPAN N, COX E, BRADLEY C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol, 2016, 65(6): 1131-1139. DOI: 10.1016/j.jhep.2016.07.021.
    [19]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [20]
    BUCK M, GARCIA-TSAO G, GROSZMANN RJ, et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients[J]. Hepatology, 2014, 59(3): 1052-1059. DOI: 10.1002/hep.26755.
    [21]
    WANG S, HUANG Y, HU W, et al. Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): A prospective multicenter study[J]. Lancet Reg Health West Pac, 2021, 6: 100072. DOI: 10.1016/j.lanwpc.2020.100072.
    [22]
    CHANG PE, TAN CK, CHEAH CC, et al. Validation of the Expanded Baveno-Ⅵ criteria for screening gastroscopy in asian patients with compensated advanced chronic liver disease[J]. Dig Dis Sci, 2021, 66(4): 1343-1348. DOI: 10.1007/s10620-020-06334-y.
    [23]
    HU Y, WEN Z. Validation and comparison of non-invasive prediction models based on liver stiffness measurement to identify patients who could avoid gastroscopy[J]. Sci Rep, 2021, 11(1): 150. DOI: 10.1038/s41598-020-80136-0.
    [24]
    DAJTI E, RAVAIOLI F, COLECCHIA A, et al. Are the Expanded Baveno Ⅵ Criteria really safe to screen compensated cirrhotic patients for high-risk varices?[J]. Dig Liver Dis, 2019, 51(3): 456-457. DOI: 10.1016/j.dld.2018.12.013.
    [25]
    KANG Y, PARK S, KIM S, et al. Validating the BAVENO Ⅵ criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix[J]. Clin Res Hepatol Gastroenterol, 2021, 45(1): 101437. DOI: 10.1016/j.clinre.2020.04.007.
    [26]
    ZHENG KI, LIU C, LI J, et al. Validation of Baveno Ⅵ and expanded Baveno Ⅵ criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis[J]. J Hepatol, 2020, 73(6): 1571-1573. DOI: 10.1016/j.jhep.2020.06.042.
    [27]
    THABUT D, BUREAU C, LAYESE R, et al. Validation of Baveno Ⅵ criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy[J]. Gastroenterology, 2019, 156(4): 997-1009. e5. DOI: 10.1053/j.gastro.2018.11.053.
    [28]
    GIANNINI EG, de MARIA C, CRESPI M, et al. Course of oesophageal varices and performance of noninvasive predictors following hepatitis C virus clearance in compensated advanced chronic liver disease[J]. Eur J Clin Invest, 2020, 50(5): e13231. DOI: 10.1111/eci.13231.
    [29]
    LEE HA, KIM SU, SEO YS, et al. Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease[J]. Liver Int, 2019, 39(6): 1071-1079. DOI: 10.1111/liv.14036.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (333) PDF downloads(49) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return